Related Experiment Video
Updated: Jun 26, 2025

Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors
Published on: June 7, 2018
The role of FERMT2 in the tumor microenvironment and immunotherapy in pan-cancer using comprehensive single-cell and
Guang-Hao Wu1, Chao He2, Gang Che2
1School of Clinical Medicine, Hangzhou Normal University Medical College, Hangzhou, China.
Abstract:
FERMT2 has been identified as a participant in integrin-linked kinase signaling pathways, influencing epithelial-mesenchymal transition and thereby affecting tumor initiation, progression, and invasion. While the character of FERMT2 in the tumor microenvironment (TME) as well as its implications for immunotherapy remain unclear. Thus, we conducted a comprehensive analysis to assess the prognostic significance of FERMT2 using Kaplan-Meier analysis. In addition, we employed enrichment analysis to uncover potential underlying molecular mechanisms. Using "Immunedeconv" package, we evaluated the immune characteristics of FERMT2 within TME. Furthermore, we determined the expression levels of FERMT2 in various cell types within TME, based on single-cell sequencing data. To confirm the co-expression of FERMT2 and markers of cancer-associated fibroblasts (CAFs), we performed multiplex immunofluorescence staining on tissue paraffin sections across various cancer types. Our analysis disclosed a significant correlation between elevated FERMT2 expression and unfavorable prognosis in specific cancer types. Furthermore, we identified a strong correlation between FERMT2 expression and diverse immune-related factors, including immune checkpoint molecules, immune cell infiltration, microsatellite instability (MSI), and tumor mutational burden (TMB). Additionally, there was a significant correlation between FERMT2 expression and immune-related pathways, particularly those associated with activating, migrating, and promoting the growth of fibroblasts in diverse cancer types. Interestingly, we observed consistent co-expression of FERMT2 in both malignant tumor cells and stromal cells, particularly within CAFs. Notably, our findings also indicated that FERMT2, in particular, exhibited elevated expression levels within tumor tissues and co-expressed with α-SMA in CAFs based on the multiplex immunofluorescence staining results.
Insights
FERMT2 influences cancer progression and impacts tumor microenvironment immunity. Elevated FERMT2 expression correlates with poor prognosis and altered immune cell infiltration, highlighting its role in cancer development and potential therapeutic targeting.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- FERMT2 is implicated in integrin-linked kinase signaling and epithelial-mesenchymal transition, processes vital for tumor initiation, progression, and invasion.
- The precise role of FERMT2 within the tumor microenvironment (TME) and its implications for cancer immunotherapy remain largely undefined.
Purpose of the Study:
- To comprehensively analyze the prognostic significance of FERMT2 in various cancer types.
- To investigate the association between FERMT2 expression and immune characteristics within the TME.
- To explore the molecular mechanisms and cellular interactions involving FERMT2 in cancer.
Main Methods:
- Kaplan-Meier analysis for prognostic significance.
- Enrichment analysis for molecular mechanisms.
- Immunedeconv package for TME immune characteristics.
- Single-cell sequencing for cell-type specific expression.
- Multiplex immunofluorescence staining for co-expression analysis.
Main Results:
- Elevated FERMT2 expression is significantly correlated with unfavorable prognosis in certain cancer types.
- FERMT2 expression strongly associates with immune checkpoint molecules, immune cell infiltration, microsatellite instability (MSI), and tumor mutational burden (TMB).
- FERMT2 correlates with fibroblast activation, migration, and growth pathways, and shows co-expression with cancer-associated fibroblasts (CAFs) and alpha-smooth muscle actin (α-SMA).
Conclusions:
- FERMT2 is a significant prognostic biomarker in specific cancers, linked to unfavorable outcomes.
- FERMT2 expression modulates the tumor immune microenvironment and fibroblast activity.
- Targeting FERMT2, particularly its co-expression in CAFs, may offer novel therapeutic strategies in cancer treatment.
Related Concept Videos
The Tumor Microenvironment
Tumor Immunotherapy

